These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29460503)

  • 1. Urinary liver-type fatty acid-binding protein in pediatric nephrotic syndrome and tubular dysfunction.
    Nishida M; Kawakatsu H; Hamaoka K
    Pediatr Int; 2018 May; 60(5):442-445. PubMed ID: 29460503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease.
    Katayama M; Ohata K; Miyazaki T; Katayama R; Wakamatsu N; Ohno M; Yamashita T; Oikawa T; Sugaya T; Miyazaki M
    J Vet Intern Med; 2020 Mar; 34(2):761-769. PubMed ID: 32087614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary NGAL, KIM-1 and L-FABP concentrations in antenatal hydronephrosis.
    Noyan A; Parmaksiz G; Dursun H; Ezer SS; Anarat R; Cengiz N
    J Pediatr Urol; 2015 Oct; 11(5):249.e1-6. PubMed ID: 26096437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2.
    Maeda Y; Suzuki A; Ishii J; Sekiguchi-Ueda S; Shibata M; Yoshino Y; Asano S; Hayakawa N; Nakamura K; Akiyama Y; Kitagawa F; Sakuishi T; Fujita T; Hashimoto S; Ozaki Y; Itoh M
    Heart Vessels; 2015 May; 30(3):362-8. PubMed ID: 24626813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
    Hofstra JM; Deegens JK; Steenbergen EJ; Wetzels JF
    Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevation of Urinary Liver-Type Fatty Acid-Binding Protein Is a Harbinger of Poor Patient Prognosis after Allogeneic Stem Cell Transplantation.
    Shingai N; Ota A; Kato K; Kondo K; Sadaga Y; Kato C; Sakai S; Kambara Y; Nabe Y; Asano K; Teshima K; Kurihara K; Ouchi F; Fujiwara H; Shimabukuro M; Inai K; Jinguji A; Toya T; Shimizu H; Najima Y; Kobayashi T; Sugaya T; Ando M; Doki N
    Transplant Cell Ther; 2024 Jan; 30(1):121.e1-121.e8. PubMed ID: 37813188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.
    Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
    Clin Nephrol; 2006 Jan; 65(1):1-6. PubMed ID: 16429835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of tubular and podocyte biomarkers in acute kidney injury.
    Matsui K; Kamijo-Ikemori A; Hara M; Sugaya T; Kodama T; Fujitani S; Taira Y; Yasuda T; Kimura K
    Clin Exp Nephrol; 2011 Apr; 15(2):220-5. PubMed ID: 21153750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary liver-type fatty acid-binding protein linked with increased risk of acute kidney injury after allogeneic stem cell transplantation.
    Shingai N; Morito T; Najima Y; Igarashi A; Kobayashi T; Doki N; Kakihana K; Ohashi K; Ando M
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2010-4. PubMed ID: 25193082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes.
    Xie Y; Xue W; Shao X; Che X; Xu W; Ni Z; Mou S
    PLoS One; 2014; 9(11):e112865. PubMed ID: 25402279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis.
    Mou S; Wang Q; Li J; Shi B; Ni Z
    Clin Chim Acta; 2012 Jan; 413(1-2):187-91. PubMed ID: 21958699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction.
    Holzscheiter L; Beck C; Rutz S; Manuilova E; Domke I; Guder WG; Hofmann W
    Clin Chem Lab Med; 2014 Apr; 52(4):537-46. PubMed ID: 24243749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease.
    Fujita D; Takahashi M; Doi K; Abe M; Tazaki J; Kiyosue A; Myojo M; Ando J; Fujita H; Noiri E; Sugaya T; Hirata Y; Komuro I
    Heart Vessels; 2015 May; 30(3):296-303. PubMed ID: 24554034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria.
    Tanaka M; Furuhashi M; Moniwa N; Maeda T; Takizawa H; Matsumoto M; Sakai A; Higashiura Y; Gocho Y; Koyama M; Ogawa Y; Miura T
    BMC Nephrol; 2020 Nov; 21(1):459. PubMed ID: 33143633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary liver-type fatty acid-binding protein predicts recovery from acute kidney injury.
    Wang L; Xue J; Chen C; Zhang Z; Deng Z; Sun Z; Xing C
    Clin Nephrol; 2015 Nov; 84(5):255-61. PubMed ID: 26396099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary excretion of liver-type FABP as a new clinical marker for the progression of obstructive nephropathy.
    Xie Y; Xu W; Wang Q; Shao X; Ni Z; Mou S
    Biomark Med; 2014; 8(4):543-56. PubMed ID: 24796620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary liver-type fatty acid-binding protein in clinically healthy elderly cats: Evaluation of its potential to detect IRIS stage 1 chronic kidney disease and borderline proteinuria.
    Kongtasai T; Paepe D; Mortier F; Marynissen S; Meyer E; Duchateau L; Daminet S
    Vet Med Sci; 2023 Jan; 9(1):3-12. PubMed ID: 36418182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary liver type fatty acid binding protein in diabetic nephropathy.
    Kamijo-Ikemori A; Sugaya T; Ichikawa D; Hoshino S; Matsui K; Yokoyama T; Yasuda T; Hirata K; Kimura K
    Clin Chim Acta; 2013 Sep; 424():104-8. PubMed ID: 23727660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan].
    Kamijo-Ikemori A; Ichikawa D; Matsui K; Yokoyama T; Sugaya T; Kimura K
    Rinsho Byori; 2013 Jul; 61(7):635-40. PubMed ID: 24205707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.
    Kim SS; Song SH; Kim IJ; Kim WJ; Jeon YK; Kim BH; Kwak IS; Lee EK; Kim YK
    Diabetes Metab Res Rev; 2014 Nov; 30(8):736-41. PubMed ID: 24687388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.